Oncology Drug Development: A Drug-Level Analysis of Subsequent Indications
Image
AUTHORS
James Motyka, PharmD; Julie Patterson, PharmD, PhD; Robert Nordyke, PhD, MS; John O’Brien, PharmD, MPH
Overview
An important component of accelerating the development of cancer treatments for patients is identifying new indications for drugs that have already been evaluated for safety and efficacy through clinical trials and regulatory review. At AMCP Nexus 2023, NPC Research Associate, James Motyka, PharmD, presented a poster summarizing historical trends in post-approval oncology drug development and discussed the impact the Inflation Reduction Act (IRA) will likely have on efforts to identify new cancer indications.
